{"id":145140,"date":"2025-03-19T17:45:44","date_gmt":"2025-03-19T16:45:44","guid":{"rendered":"https:\/\/www.startupbusiness.it\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/"},"modified":"2025-03-19T18:00:17","modified_gmt":"2025-03-19T17:00:17","slug":"genenta-science-eur-20-million-funding-from-enea-tech","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/","title":{"rendered":"Genenta Science, EUR 20 million funding from Enea Tech"},"content":{"rendered":"\n<p><strong>Genenta Science, a Nasdaq-listed biotech scaleup pioneering immuno-oncology and cell therapy, announces a EUR 20 million financing through the issuance of a Mandatory Convertible Bond<\/strong> to <strong>ENEA Tech and Biomedical to support the expansion of its pipeline through the advancement of Temferon in metastatic renal cell carcinoma (mRCC).<\/strong> <\/p>\n\n<p>Enea Tech, a private foundation supervised by the Ministry of Enterprise and Industry, manages over EUR 1.7 billion of assets under management through two funds. With in-depth knowledge of the biomedical sector, Enea Tech has all the tools at its disposal to identify and support high-potential biotechnology companies. <\/p>\n\n<p><strong>&#8216;Before committing to this investment, Enea Tech conducted thorough scientific and legal due diligence. We spent several months in negotiations,&#8217; says Pierluigi Paracchi, CEO of Genenta. &#8216;We believe that the terms of the mandatory convertible bond are indicative of the potential long-term value of Genenta&#8217;s shares. <\/strong> The bond will not result in immediate dilution for Genenta&#8217;s shareholders and is expected to provide the necessary capital to meet the milestones of the company&#8217;s new mRCC study. The conversion into shares is scheduled for March 2028, followed by a two-year lock-up period. Of course, the process will be accelerated in the event of a change of control of our company. Enea Tech is a trusted partner with strong financial backing, which will help ensure the financial stability needed to advance the validation of the Temferon platform and our ability to pursue strategic collaborations.&#8221;   <\/p>\n\n<p>February data from the Phase 1\/2a uMGMT Glioblastoma Multiforme (GBM) study show an increase in the percentage of patients surviving two years, which now reaches 29%, up from 25% in October. In addition, there is a marginal improvement in median overall survival, which is now 17 months. Historical data showed that the overall survival of uMGMT patients undergoing standard care was about 14% at two years, with a median overall survival of 13-15 months. Notably, the Phase 1\/2a study in metastatic renal cell carcinoma has recently started enrolling patients, further strengthening the company&#8217;s clinical pipeline for Temferon.   <\/p>\n\n<p><strong>Luigi Naldini, co-founder of Genenta, adds: &#8216;We are continuing to demonstrate at the preclinical and clinical level Temferon&#8217;s ability to reprogramme the tumour microenvironment, <\/strong>which in turn induces cell-mediated immune responses, as suggested by Genenta&#8217;s ongoing GBM study and which will be tested in the Company&#8217;s mRCC study&#8217;.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development<\/p>\n","protected":false},"author":125,"featured_media":145138,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1317],"tags":[1350,1143,1137,1323],"companies":[2393],"journalist":[1518],"class_list":["post-145140","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-biotech-en","tag-investments","tag-italy-en","tag-scaleup-en","companies-genenta-science-en","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","width":150,"height":94,"crop":false,"srcset":false,"alt":"biotech tumori"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","width":1024,"height":639,"crop":false,"srcset":false,"alt":"biotech tumori"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","width":1280,"height":799,"crop":false,"srcset":false,"alt":"biotech tumori"}},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genenta Science, EUR 20 million funding from Enea Tech<\/title>\n<meta name=\"description\" content=\"Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta Science, EUR 20 million funding from Enea Tech\" \/>\n<meta property=\"og:description\" content=\"Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T16:45:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-19T17:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"799\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Genenta Science, EUR 20 million funding from Enea Tech\",\"datePublished\":\"2025-03-19T16:45:44+00:00\",\"dateModified\":\"2025-03-19T17:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/\"},\"wordCount\":390,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/mc_12202111.webp\",\"keywords\":[\"biotech\",\"investments\",\"italy\",\"Scaleup\"],\"articleSection\":[\"Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/\",\"name\":\"Genenta Science, EUR 20 million funding from Enea Tech\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/mc_12202111.webp\",\"datePublished\":\"2025-03-19T16:45:44+00:00\",\"dateModified\":\"2025-03-19T17:00:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genenta-science-eur-20-million-funding-from-enea-tech\\\/145140\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/mc_12202111.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/mc_12202111.webp\",\"width\":1280,\"height\":799,\"caption\":\"biotech tumori\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta Science, EUR 20 million funding from Enea Tech","description":"Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/","og_locale":"en_US","og_type":"article","og_title":"Genenta Science, EUR 20 million funding from Enea Tech","og_description":"Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development","og_url":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/","og_site_name":"Startupbusiness.it","article_published_time":"2025-03-19T16:45:44+00:00","article_modified_time":"2025-03-19T17:00:17+00:00","og_image":[{"width":1280,"height":799,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Genenta Science, EUR 20 million funding from Enea Tech","datePublished":"2025-03-19T16:45:44+00:00","dateModified":"2025-03-19T17:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/"},"wordCount":390,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","keywords":["biotech","investments","italy","Scaleup"],"articleSection":["Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/","url":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/","name":"Genenta Science, EUR 20 million funding from Enea Tech","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","datePublished":"2025-03-19T16:45:44+00:00","dateModified":"2025-03-19T17:00:17+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"Enea Tech and Biomedical Foundation underwrites a convertible bond to support scaleup development","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/genenta-science-eur-20-million-funding-from-enea-tech\/145140\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/03\/mc_12202111.webp","width":1280,"height":799,"caption":"biotech tumori"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Funding News"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/145140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=145140"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/145140\/revisions"}],"predecessor-version":[{"id":145141,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/145140\/revisions\/145141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/145138"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=145140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=145140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=145140"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=145140"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=145140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}